tiRNA‐Gly‐GCC‐001 in major depressive disorder: Promising diagnostic and therapeutic biomarker

Abstract

AbstractBackground and PurposeIn major depressive disorder (MDD), exploration of biomarkers will be helpful in diagnosing the disorder as well as in choosing a treatment and predicting the treatment response. Currently, tRNA‐derived small ribonucleic acids (tsRNAs) have been established as promising non‐invasive biomarker candidates that may enable a more reliable diagnosis or monitoring of various diseases. Herein, we aimed to explore tsRNA expression together with functional activities in MDD development.Experimental ApproachSerum samples were obtained from patients with MDD and healthy controls, and small RNA sequencing (RNA‐Seq) was used to profile tsRNA expression. Dysregulated tsRNAs in MDD were validated by quantitative real‐time polymerase chain reaction (qRT‐PCR). The diagnostic utility of specific tsRNAs and the expression of these tsRNAs after antidepressant treatment were analysed.Key ResultsIn total, 38 tsRNAs were significantly differentially expressed in MDD samples relative to healthy individuals (34 up‐regulated and 4 down‐regulated). qRT‐PCR was used to validate the expression of six tsRNAs that were up‐regulated in MDD (tiRNA‐1:20‐chrM.Ser‐GCT, tiRNA‐1:33‐Gly‐GCC‐1, tRF‐1:22‐chrM.Ser‐GCT, tRF‐1:31‐Ala‐AGC‐4‐M6, tRF‐1:31‐Pro‐TGG‐2 and tRF‐1:32‐chrM.Gln‐TTG). Interestingly, serum tiRNA‐Gly‐GCC‐001 levels exhibited an area under the ROC curve of 0.844. Moreover, tiRNA‐Gly‐GCC‐001 is predicted to suppress brain‐derived neurotrophic factor (BDNF) expression. Furthermore, significant tiRNA‐Gly‐GCC‐001 down‐regulation was evident following an 8‐week treatment course and served as a promising baseline predictor of patient response to antidepressant therapy.Conclusion and ImplicationsOur current work reports for the first time that tiRNA‐Gly‐GCC‐001 is a promising MDD biomarker candidate that can predict patient responses to antidepressant therapy.